Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyBaylor Scott & White TAVR TPVI TMVR Coverage Updat…
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 204

    Transcatheter Valve Replacement or Repair

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 204 alerts

    Get alerted when Policy 204 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, and coding guidance for transcatheter aortic, mitral and pulmonary valve replacement or repair for Baylor Scott & White Health Plan members.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyTranscatheter Valve Replacement or Repair
    Policy CodePolicy 204
    Change TypeCriteria added and InterQual specified
    Effective Date06/01/2026
    Last ReviewApr 23, 2026
    Next Review Date04/23/2027
    Key ActionObtain prior authorization and confirm medical necessity criteria are met before scheduling transcatheter valve procedures.
    SourceLink
    POLICY UPDATE CHANGES

    Updated criteria for TPVI (transcatheter pulmonary valve implantation).

    Added InterQual as source for medical necessity for TMVR.

    Removed statement that 'Medicare NCD or LCD specific InterQual criteria may be used when available.'

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    TAVR, TPVI, TMVRservices covered by policy
    Prior authorization requiredauthorization requirement
    Version 9.0policy version
    06/01/2026effective date

    Medical Necessity Criteria for Transcatheter Valve Procedures

    TAVR (Transcatheter Aortic Valve Replacement)

    Covered when ALL of the following are met:

    TAVR medical necessity: Member has symptomatic aortic valve stenosis and meets device FDA-approved indications or, for Commercial plans, InterQual criteria; for Medicare plans, evaluate against NCD 20.32 and applicable facility/registry requirements.

    TAVR is considered experimental, investigational and/or unproven for other indications.

    TPVI (Transcatheter Pulmonary Valve Implantation)

    Covered when ALL of the following are met:

    TPVI medical necessity: Member has prior repair of congenital heart disease with right ventricular outflow tract (RVOT) dysfunction and one of: moderate/severe pulmonary regurgitation OR moderate/severe right ventricular to pulmonary artery (RV-PA) stenosis; and target anatomy includes a surgical RVOT conduit, native RVOT, RVOT with transannular patching, or a bioprosthetic pulmonary valve.

    TPVI is considered experimental, investigational and/or unproven for all other indications.

    TMVR (Transcatheter Mitral Valve Repair)

    Covered when ALL of the following are met:

    TMVR medical necessity: Patient has symptomatic mitral regurgitation and is considered high risk for traditional open‑heart mitral valve surgery; the device is FDA‑approved for the indication. For Commercial plans use InterQual; for Medicare lines of business, evaluate against NCD 20.33 and applicable facility/registry requirements.

    Transcatheter mitral valve implantation/replacement (TMVI) is considered experimental, investigational and/or unproven for all indications.

    This policy defines medical necessity and prior authorization requirements for transcatheter valve procedures including TAVR (transcatheter aortic valve replacement), TPVI (transcatheter pulmonary valve implantation), and TMVR (transcatheter mitral valve repair). Prior authorization is required for these procedures; providers must review the member's Evidence of Coverage or Summary Plan Description and confirm the applicable medical necessity criteria and any plan-specific coverage details before scheduling services. For Medicare and Medicaid lines, applicable NCD/LCD or state Medicaid manuals apply and must be followed when available.

    Transcatheter mitral valve implantation/replacement (TMVI) is considered experimental, investigational and/or unproven for all indications and is therefore not medically necessary under this policy. TMVI devices and procedures that do not have FDA approval for the intended indication are not covered.

    Procedure and Diagnosis Coding

    Covered CPT CodesCPTCovered
    33361TAVR with prosthetic valve; percutaneous femoral artery approach
    33362TAVR with prosthetic valve; open femoral artery approach
    33363TAVR with prosthetic valve; open axillary artery approach
    33364TAVR with prosthetic valve; open iliac artery approach
    33365TAVR with prosthetic valve; transaortic approach (eg, median sternotomy, mediastinotomy)
    33366TAVR with prosthetic valve; transapical exposure (eg, left thoracotomy)
    33418Transcatheter mitral valve repair, percutaneous approach, including transseptal puncture when performed; initial prosthesis
    33477Transcatheter pulmonary valve implantation, percutaneous approach, including pre-stenting of the valve delivery site
    0345TTranscatheter mitral valve repair percutaneous approach via the coronary sinus (MitraClip)
    Not Covered CPT CodesCPTNot Covered
    0483TTranscatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; percutaneous
    0484TTranscatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; transthoracic
    Potentially applicable ICD-10 CodesICD-10
    I06.0Rheumatic aortic stenosis
    I08.0Rheumatic disorders of both mitral and aortic valves
    I34.0 - I34.9Mitral valve disorders (symptomatic degenerative mitral regurgitation)
    I35.0 - I35.9Nonrheumatic aortic valve disorders (stenosis)
    T82.01xBreakdown (mechanical) of heart valve prosthesis (degenerated bioprosthetic aortic valve)
    T82.03xLeakage of heart valve prosthesis (degenerated bioprosthetic aortic valve)
    T82.857Stenosis of cardiac prosthetic devices, implants and grafts (degenerated bioprosthetic aortic valve)
    I05.xRheumatic mitral valve disease
    Q23.2 - Q23.8Congenital mitral valve disease
    Z95.2Presence of prosthetic heart valve
    TPVI eligibility — key elements
    Clinical indicationsMember has prior repair of congenital heart disease with right ventricular outflow tract (RVOT) dysfunction AND one of: moderate or severe pulmonary regurgitation (PR) OR moderate or severe right ventricular–to–pulmonary artery (RV‑PA) stenosis.
    Anatomic substrate requiredTarget anatomy must include one of: surgical RVOT conduit, native RVOT, RVOT with transannular patching, or bioprosthetic pulmonary valve.
    Coverage stance for other usesTPVI is considered experimental, investigational and/or unproven for all other indications (not covered).
    Related procedural contextApplies to percutaneous transcatheter pulmonary valve implantation for patients meeting above clinical and anatomic criteria.

    Authorization, Documentation, and Provider Responsibilities

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all transcatheter valve procedures (TAVR, TPVI, TMVR) prior to scheduling or performing the service. Lack of prior authorization may result in claim denial or delayed payment.

    • Applies to TAVR, TPVI, TMVR and related transcatheter valve procedures.
    • Providers should obtain authorization using the payer's established prior authorization process and include heart team assessment documentation when applicable.
    Documentation Required

    Review Member Evidence of Coverage / Plan Documents

    Providers must review the member's Evidence of Coverage (EOC) or Summary Plan Description (SPD) to confirm benefit coverage, member-specific limitations, and any plan exclusions prior to initiating authorization or treatment. For Medicare members, providers must also confirm applicable NCDs/LCDs and Medicare-specific requirements.

    Clinical Background and Rationale

    Aortic stenosis is the most commonly acquired valvular heart disease. Surgical aortic valve replacement remains the standard treatment, but less invasive transcatheter approaches such as TAVR/TAVI provide an alternative for patients who are at prohibitive or high surgical risk. For members with symptomatic aortic stenosis, TAVR may be considered medically necessary when performed with FDA‑approved devices and indications; for Commercial plans InterQual criteria are used and for Medicare plans NCD 20.32 and applicable facility/registry requirements should be applied.

    Transcatheter pulmonary valve implantation (TPVI) addresses right ventricular outflow tract (RVOT) dysfunction in patients with prior congenital heart disease repair. TPVI may be considered medically necessary when the member has prior repair of congenital heart disease with RVOT dysfunction and one of the following: moderate/severe pulmonary regurgitation or moderate/severe right ventricular–to–pulmonary artery stenosis, and target anatomy suitable for TPVI (surgical RVOT conduit, native RVOT, RVOT with transannular patching, or bioprosthetic pulmonary valve).

    Transcatheter mitral valve repair (TMVR), such as edge‑to‑edge leaflet repair (e.g., MitraClip), is used to reduce mitral regurgitation in symptomatic patients who are high risk for traditional open surgical repair; multidisciplinary heart team evaluation is recommended for candidate selection. For Commercial plans, InterQual criteria are used to determine medical necessity; for Medicare lines, NCD 20.33 and any facility/registry requirements should be followed.

    Procedure Definitions and Terms

    TAVR/TAVI definition
    DefinitionTranscatheter aortic valve implantation/replacement (TAVR/TAVI): percutaneous placement of a prosthetic aortic valve that repairs the valve without removing the native, damaged valve by wedging a replacement valve into the aortic valve position.
    Clinical roleLess invasive alternative to surgical aortic valve replacement for patients with severe symptomatic aortic stenosis who are at prohibitive or high surgical risk.
    Procedure noteNot intended to replace surgical care for most patients; evaluate against device FDA indications and applicable payer/Medicare coverage rules.
    TMVR definition and context
    DefinitionTranscatheter mitral valve repair (TMVR): edge‑to‑edge leaflet repair (e.g., MitraClip) that clips together a portion of the mitral valve leaflets to reduce mitral regurgitation.
    FDA‑approved device

    Policy Changes and Review Dates

    2012-11-29policy_created

    Policy created after TAC review (new policy).

    2015-10-22coverage_added

    TMVR coverage was added to the policy.

    2018-09-25criteria_added

    Criteria for pulmonary valve (TPVI) were added to the policy.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyTranscatheter Valve Replacement or Repair
    Policy CodePolicy 204
    Change TypeCriteria added and InterQual specified
    Effective Date06/01/2026
    Last ReviewApr 23, 2026
    Next Review Date04/23/2027
    Key ActionObtain prior authorization and confirm medical necessity criteria are met before scheduling transcatheter valve procedures.
    SourceLink
    On This Page
    Medical Necessity Criteria for Transcatheter Valve ProceduresProcedure and Diagnosis CodingAuthorization, Documentation, and Provider ResponsibilitiesClinical Background and RationaleProcedure Definitions and TermsPolicy Changes and Review Dates
  1. Reference the member's EOC/SPD for benefit determinations and any cost-sharing or coverage limits.
  2. For Medicare: verify NCD 20.32 (TAVR) and NCD 20.33 (TMVR) or relevant LCDs; follow Medicare facility/registry requirements as applicable.
  3. Step Therapy

    Step Therapy Not Applicable

    There are no step therapy or other pre-authorization sequencing requirements beyond demonstrating medical necessity and an appropriate multidisciplinary heart team assessment for TMVR candidates.

    • No step therapy protocols apply for transcatheter mitral valve repair beyond the documented clinical criteria and heart team evaluation.
    • Standard medical necessity review applies; do not require prior trials of alternate therapies as a formal step-therapy pathway.
    Denial Risk

    Denial Risk — Authorization and Documentation

    Failure to obtain prior authorization when required may lead to denial of coverage or payment. Ensure submitted documentation clearly supports medical necessity, heart team recommendations, and alignment with the plan's coverage criteria.

    • Include operative/ procedure reports, diagnostic imaging, heart team notes, and prior treatment history as part of the authorization request.
    • Confirm any device-specific FDA indication and member eligibility per the plan before scheduling.
    Abbott’s MitraClip is currently the only FDA‑approved TMVR device referenced in this policy (approved for moderate‑severe or severe primary MR).
    Candidate evaluationMultidisciplinary heart team evaluation is recommended for TMVR candidates; use InterQual for Commercial lines and NCD 20.33 for Medicare lines where applicable.
    TPVI definition
    DefinitionTranscatheter pulmonary valve implantation (TPVI): percutaneous implantation of a pulmonary valve for patients with prior congenital heart disease repair and RVOT dysfunction (meeting specified clinical and anatomic criteria).
    Indications summaryUsed to treat RVOT dysfunction manifesting as moderate/severe pulmonary regurgitation or moderate/severe RV‑PA stenosis in appropriate anatomy (conduit, native RVOT, transannular patch, or bioprosthetic pulmonary valve).
    Coverage limitationTPVI is considered experimental, investigational and/or unproven for all indications not meeting the listed criteria.
    2024-06-10formatting_update

    Formatting changes and added hyperlinks to CMS and TMPPM resources; note sections updated to align with CMS requirements and business entity changes.

    2025-08-11administrative_revision

    Removed statement that 'Medicare NCD or LCD specific InterQual criteria may be used when available.' (administrative).

    2026-04-23material_revision

    Updated criteria for TPVI and added InterQual as the source for medical necessity for TMVR; Medicare hyperlinks and references updated.

    2026-06-01effective_dateLatest

    Policy effective date reflecting the current version and incorporated revisions effective 06/01/2026.